公开(公告)号：US20240238380A1

公开(公告)日：2024-07-18

申请号：US18562322

申请日：2022-05-20

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Do Hoon KIM ,  Mi Kyeong JU ,  Hyun Ho CHOI ,  Han Na HONG ,  Junhwan KIM

IPC: A61K38/26 ,  A61K38/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K38/1841 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes, obesity, dyslipidemia, or metabolic syndrome by administering in combination with a GLP-1 (glucagon-like peptide-1) receptor agonist, comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20200024318A1

公开(公告)日：2020-01-23

申请号：US15768865

申请日：2016-10-28

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan KIM ,  Seyoung LIM ,  Minji SEO ,  Hyun Ho CHOI ,  Dohoon KIM ,  Mi Kyeong JU ,  Ju-Young PARK ,  Seul Gi KIM ,  Sangmyoun LIM ,  Jong Gyun KIM ,  Su Youn NAM

IPC: C07K14/50 ,  C07K14/605 ,  C07K14/575 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P1/16

Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

公开(公告)号：US20220002368A1

公开(公告)日：2022-01-06

申请号：US17478628

申请日：2021-09-17

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan KIM ,  Seyoung LIM ,  Minji SEO ,  Hyun Ho CHOI ,  Dohoon KIM ,  Mi Kyeong JU ,  Ju-Young PARK ,  Seul Gi KIM ,  Sangmyoun LIM ,  Jong Gyun KIM ,  Su Youn NAM

IPC: C07K14/50 ,  C07K14/575 ,  C07K14/605

Abstract: A dual function protein is disclosed. The dual function protein may be prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. The dual function protein has improved pharmacological efficacy, in vivo duration and protein stability. The dual function protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

公开(公告)号：US20180305428A1

公开(公告)日：2018-10-25

申请号：US15768616

申请日：2016-10-28

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan KIM ,  Seyoung LIM ,  Minji SEO ,  Hyun Ho CHOI ,  Dohoon KIM ,  Mi Kyeong JU ,  Ju-Young PARK ,  Byung Hyun CHOI ,  Jun Kyung LEE ,  Jong Gyun KIM ,  Su Youn NAM

IPC: C07K14/50 ,  A61P3/10 ,  A61P3/04 ,  A61P1/16

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  C07K2319/30

Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

公开(公告)号：US20240279296A1

公开(公告)日：2024-08-22

申请号：US18491616

申请日：2023-10-20

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan KIM ,  Seyoung LIM ,  Minji SEO ,  Hyun Ho CHOI ,  Dohoon KIM ,  Mi Kyeong JU ,  Ju-Young PARK ,  Byung Hyun CHOI ,  Jun Kyung LEE ,  Jong Gyun KIM ,  Su Youn NAM

IPC: C07K14/50 ,  A61K38/18 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07K14/50 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61K38/1825 ,  C07K2319/30

Abstract: A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

公开(公告)号：US20240082354A1

公开(公告)日：2024-03-14

申请号：US18513613

申请日：2023-11-19

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Ji Eun YANG ,  Do Hoon KIM ,  Sukyung KIM ,  Bo Ra SIM ,  Yunji LEE ,  Nayeon YANG ,  Junhwan KIM

IPC: A61K38/18 ,  A61P1/16

CPC classification number: A61K38/1841 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), comprising a GDF15 (growth differentiation factor-15) variant, a long-acting GDF15 fusion protein, or a long-acting GDF15 fusion protein dimer as an active ingredient.

公开(公告)号：US20230002460A1

公开(公告)日：2023-01-05

申请号：US17779932

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Young Bong PARK ,  Sukyung KIM ,  Bo Ra SIM ,  Wonee CHONG ,  Hyun Ho CHOI ,  Ji Eun YANG ,  Mi Kyeong JU ,  Won Tae KIM ,  Youn Woo LEE ,  Junhwan KIM

IPC: C07K14/475 ,  C12N15/63

Abstract: A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed. The GDF15 variant or long-acting GDF15 fusion protein is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect. Therefore, a pharmaceutical composition containing, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or a dimer of the fusion protein, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. Furthermore, the pharmaceutical composition can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.

公开(公告)号：US20220002367A1

公开(公告)日：2022-01-06

申请号：US17478600

申请日：2021-09-17

Applicant: YUHAN CORPORATION

Inventor： Jun Hwan KIM ,  Seyoung LIM ,  Minji SEO ,  Hyun Ho CHOI ,  Dohoon KIM ,  Mi Kyeong JU ,  Ju-Young PARK ,  Byung Hyun CHOI ,  Jun Kyung LEE ,  Jong Gyun KIM ,  Su Youn NAM

IPC: C07K14/50 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

Abstract: A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.